Literature DB >> 9989832

Reduced growth rate and transformation phenotype of the prostate cancer cells by an interferon-inducible protein, p202.

D H Yan1, Y Wen, B Spohn, D Choubey, J U Gutterman, M C Hung.   

Abstract

Interferons (IFNs) can exert cytostatic and immunomodulatory effects on carcinoma cells. In particular, growth inhibition of human prostate carcinoma by IFNs has been demonstrated both in vitro and in vivo. p202 is a 52 kd nuclear phosphoprotein known to be induced by IFNs. In this report, we showed that the expression of p202 was associated with an anti-proliferative effect on human prostate cancer cells. More importantly, cells that expressed p202 showed reduced ability to grow in soft-agar, indicating a loss of transformation phenotype. Our data suggest that p202 is a growth inhibitor gene in prostate cancer cells and its expression may also suppress transformation phenotype of prostate cancer cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9989832     DOI: 10.1038/sj.onc.1202369

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  4 in total

Review 1.  Transcription and growth regulatory functions of the HIN-200 family of proteins.

Authors:  R W Johnstone; J A Trapani
Journal:  Mol Cell Biol       Date:  1999-09       Impact factor: 4.272

2.  Interferon-gamma reduces cell surface expression of annexin 2 and suppresses the invasive capacity of prostate cancer cells.

Authors:  Claire Hastie; John R Masters; Stephen E Moss; Soren Naaby-Hansen
Journal:  J Biol Chem       Date:  2008-01-22       Impact factor: 5.157

Review 3.  p204, a p200 family protein, as a multifunctional regulator of cell proliferation and differentiation.

Authors:  Yi Luan; Peter Lengyel; Chuan-Ju Liu
Journal:  Cytokine Growth Factor Rev       Date:  2008-11-21       Impact factor: 7.638

Review 4.  MTA1--a stress response protein: a master regulator of gene expression and cancer cell behavior.

Authors:  Rui-An Wang
Journal:  Cancer Metastasis Rev       Date:  2014-12       Impact factor: 9.264

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.